DOCSLIB.ORG

High-Grade Ovarian Serous Carcinoma Presenting As Androgenetic Alopecia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
High-Grade Ovarian Serous Carcinoma Presenting As Androgenetic Alopecia CASE LETTER High-Grade Ovarian Serous Carcinoma Presenting as Androgenetic Alopecia Anna Eversman, BS; Elisabeth Tracey, MD; Christine B. Warren, MD, MS copy range in most female patients with hair loss, suggesting 2 PRACTICE POINTS the presence of additional contributing factors. Given the high prevalence of female pattern hair • Laboratory assessment for possible androgen excess should be performed in patients with female pattern loss and the harm of overlooking androgen excess and hair loss and include baseline serum total testoster- an androgen-secretingnot neoplasm, dermatologists must one and dehydroepiandrosterone sulfate. recognize indications for further evaluation. Additional • Rapid onset or worsening of clinical hyperandrogen- signs of hyperandrogenism, such as menstrual irreg- ism should raise suspicion of malignancy. ularities, acne, hirsutism, anabolic appearance, voice 3 • Transvaginal ultrasonography and possible pel- deepening, and clitoromegaly, are reasons for concern. vic magnetic resonance imaging are indicated forDo Elevated serum androgen levels also should raise suspi- patients with clinical hyperandrogenism and an iso- cion of malignancy. Historically, a total testosterone level lated testosterone level elevation. above 200 ng/dL or a dehydroepiandrosterone sulfate (DHEA-S) level greater than 700 µg/dL prompted evalu- ation for a tumor.4 More recent studies show that tumor- induced increases in serum androgen levels are highly To the Editor: variable, challenging the utility of these cutoffs.5 Female pattern hair loss is common, and the literature A 70-year-old woman presented with hair loss over suggests that up to 56% of women experience hair thin- the last 12 years with accentuated thinning on the frontal ning in their lifetime, with increased prevalence in older and vertex scalp. The patient’s primary care physician women.1 PathophysiologyCUTIS is incompletely understood previously made a diagnosis of androgenetic alopecia and and involves the nonscarring progressive miniaturization recommended topical minoxidil. Although the patient of hair follicles, causing decreased production of terminal had a history of excess facial and body hair since young hairs relative to more delicate vellus hairs. Because vellus adulthood, she noted a progressive increase in the den- hairs have a shorter anagen growth phase than terminal sity of chest and back hair, prominent coarsening of the hairs, hair loss is expedited. Androgen excess, when pres- texture of the facial and body hair, and new facial acne in ent, hastens the process by inducing early transition of the last 3 years. Prior to these changes, the density and hair follicles from the anagen phase to the senescent telo- texture of the scalp and body hair had been stable for gen phase. Serum testosterone levels are within reference many years. Ms. Eversman and Dr. Warren are from the Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Ohio. Dr. Warren also is from and Dr. Tracey is from the Department of Dermatology, Cleveland Clinic. The authors report no conflict of interest. Correspondence: Christine B. Warren, MD, MS, Department of Dermatology, Cleveland Clinic, 9500 Euclid Ave A61, Cleveland, OH 44195 ([email protected]). doi:10.12788/cutis.0151 E12 I CUTIS® WWW.MDEDGE.COM/DERMATOLOGY Copyright Cutis 2020. No part of this publication may be reproduced, stored, or transmitted without the prior written permission of the Publisher. MALIGNANCIES AND ANDROGENETIC ALOPECIA Although other postmenopausal females in the presenting to dermatology. Although most cases of patient’s family displayed patterned hair loss, they did androgenetic alopecia are isolated or secondary to benign not possess coarse and dense hair on the face and trunk. conditions, such as polycystic ovary syndrome or non- Her family history was notable for ovarian cancer in her classic congenital adrenal hyperplasia, a small minority mother (in her 70s) and breast cancer in her maternal (<1% of women presenting with signs of hyperandrogen- grandmother (in her 80s). ism) have an androgen-secreting tumor.6 A review of systems was notable only for decreased Rapid onset or worsening of clinical hyperandrogen- energy. Physical examination revealed a well-appearing ism, as seen in our patient, should raise concern for older woman with coarse terminal hair growth on the pathology; serum total testosterone and DHEA-S levels cheeks, submental chin, neck, chest, back, and forearms. should be evaluated. Abnormally elevated serum andro- Scalp examination indicated diffusely decreased hair den- gens are associated with malignancy; however, there is sity, most marked over the vertex, crown, and frontal scalp, variability in the recommended cutoff levels to prompt without scale, erythema, or loss of follicular ostia (Figure 1). suspicion for an androgen-producing tumor and further Laboratory evaluation revealed elevated levels workup in postmenopausal women.7 In the case of tes- of total testosterone (106 ng/dL [reference range, tosterone elevation, classic teaching designates a testos- <40 ng/dL]) and free testosterone (32.9 pg/mL [reference terone level greater than 200 ng/dL as the appropriate range, 1.8–10.4 pg/mL]) but a DHEA-S level within ref- threshold for concern, but this level is now debated. In erence range, suggesting an ovarian source of androgen a series of women with hyperandrogenism referred to excess. The CA-125 level was elevated (89 U/mL [refer- a center for suspicion of an androgen-secreting tumor, ence range, <39 U/mL]). those with a tumor had, on average, a significantly higher Pelvic ultrasonography was suspicious for an ovarian (260 ng/dL) testosterone level than women who had pathology. Follow-up pelvic magnetic resonance imaging other causes (90 ng/dL)(copyP<.05).6 The authors of that (MRI) demonstrated a 2.5-cm mass abutting the left ovary study proposed a cutoff of 1.4 ng/mL because women in (Figure 2). The patient was given a diagnosis of stage IIIA their series who had a tumor were 8.4 times more likely high-grade ovarian serous carcinoma with lymph node to have a testosterone level of 1.4 ng/mL or higher than involvement. Other notable findings from the workup women without a tumor. However, this cutoff was only included a BRCA2 mutation and concurrent renal cell 92%not sensitive and 70% specific.6 The degree of androgen carcinoma. After bilateral salpingo-oophorectomy, par- elevation is highly variable in both tumorous and benign tial nephrectomy, and chemotherapy with carboplatin pathologies with notable overlap, challenging the notion and paclitaxel, the testosterone level returned to within of a clear cutoff. reference range and remained stable for the next 2 years Imaging is indicated for a patient presenting with both of follow-up. Doclinical and biochemical hyperandrogenism. Patients with Female pattern hair loss is common in postmeno- an isolated testosterone level elevation can be evaluated pausal women and is a frequent concern in patients with transvaginal ultrasonography; however, detection CUTIS A B FIGURE 1. A and B, Diffusely decreased hair density, most marked over the vertex, crown, and frontal scalp, without scale, erythema, or loss of follicular ostia. WWW.MDEDGE.COM/DERMATOLOGY VOL. 106 NO. 6 I DECEMBER 2020 E13 Copyright Cutis 2020. No part of this publication may be reproduced, stored, or transmitted without the prior written permission of the Publisher. MALIGNANCIES AND ANDROGENETIC ALOPECIA A B FIGURE 2. A and B, Axial T1–weighted and sagittal T2–weighted pelvic magnetic resonance imaging, respectively, demonstrated a 2.5-cm mass (red arrows) abutting the left ovary. copy and characterization of malignancies is highly dependent REFERENCES on the skill of the examiner.8,9 The higher sensitivity and 1. Carmina E, Azziz R, Bergfeld W, et al. Female pattern hair loss and specificity of pelvic MRI reduces the likelihood of missing androgen excess: a report from the multidisciplinary androgen excess notand PCOS committee. J Clin Endocrinol Metab. 2019;104:2875-2891. a malignancy and unnecessary surgery. Tumors too small 2. Herskovitz I, Tosti A. Female pattern hair loss. Int J Endocrinol Metab. 10 to be visualized by MRI rarely are malignant. 2013;11:e9860. Sex cord-stromal cell tumors, despite representing 3. Rothman MS, Wierman ME. How should postmenopausal androgen fewer than 10% of ovarian tumors, are responsible for excess be evaluated? Clin Endocrinol (Oxf). 2011;75:160-164. the majority of androgen-secreting malignancies. Our 4. Derksen J, Nagesser SK, Meinders AE, et al. Identification of virilizing Do adrenal tumors in hirsute women. N Engl J Med. 1994;331:968-973. patient presented with clinical hyperandrogenism with an 5. Kaltsas GA, Isidori AM, Kola BP, et al. The value of the low-dose elevated testosterone level in the setting of a serous ovar- dexamethasone suppression test in the differential diagnosis of ian carcinoma, which is an epithelial neoplasm. Epithelial hyperandrogenism in women. J Clin Endocrinol Metab. 2003; tumors are the most common type of ovarian tumor 88:2634-2643. and typically are nonfunctional, though they have been 6. Sarfati J, Bachelot A, Coussieu C, et al; Study Group Hyperandrogenism in Postmenopausal Women. Impact of clinical, hormonal, radiological, reported to cause hyperandrogenism through indirect immunohistochemical studies on the diagnosis of postmenopausal mechanisms. It is thought that both benign and malig- hyperandrogenism. Eur J Endocrinol. 2011;165:779-788. nant epithelial tumors can induce stromal hyperplasia or 7. Glintborg D, Altinok ML, Petersen KR, et al. Total testosterone levels 6 are often more than three times elevated in patients with androgen- luteinization, leading to an increase in androgen levels. secreting tumours. BMJ Case Rep. 2015;2015:bcr2014204797. Due to the high prevalence of androgenetic alo- CUTIS 8. Iyer VR, Lee SI. MRI, CT, and PET/CT for ovarian cancer detection pecia and hirsutism in aging women, identification of and adnexal lesion characterization. AJR Am J Roentgenol. 2010; androgen-secreting neoplasms by clinical presentation 194:311-321. is challenging. A wide range of serum testosterone levels 9. Rauh-Hain JA, Krivak TC, Del Carmen MG, et al.
Load more

Recommended publications
  • Anatomy and Physiology of Hair
    Chapter 2 Provisional chapter Anatomy and Physiology of Hair Anatomy and Physiology of Hair Bilgen Erdoğan ğ AdditionalBilgen Erdo informationan is available at the end of the chapter Additional information is available at the end of the chapter http://dx.doi.org/10.5772/67269 Abstract Hair is one of the characteristic features of mammals and has various functions such as protection against external factors; producing sebum, apocrine sweat and pheromones; impact on social and sexual interactions; thermoregulation and being a resource for stem cells. Hair is a derivative of the epidermis and consists of two distinct parts: the follicle and the hair shaft. The follicle is the essential unit for the generation of hair. The hair shaft consists of a cortex and cuticle cells, and a medulla for some types of hairs. Hair follicle has a continuous growth and rest sequence named hair cycle. The duration of growth and rest cycles is coordinated by many endocrine, vascular and neural stimuli and depends not only on localization of the hair but also on various factors, like age and nutritional habits. Distinctive anatomy and physiology of hair follicle are presented in this chapter. Extensive knowledge on anatomical and physiological aspects of hair can contribute to understand and heal different hair disorders. Keywords: hair, follicle, anatomy, physiology, shaft 1. Introduction The hair follicle is one of the characteristic features of mammals serves as a unique miniorgan (Figure 1). In humans, hair has various functions such as protection against external factors, sebum, apocrine sweat and pheromones production and thermoregulation. The hair also plays important roles for the individual’s social and sexual interaction [1, 2].
    [Show full text]
  • Permanent Hair Reduction Is a Lasting Solution That Takes Away the Everyday Hassle of Dealing with Unwanted Facial and Body Hair
    Embrace the freedom and confidence that Fall in love with BE FREE TO LOOK YOUR comes with permanent the lasting results BEST EVERY DAY WITH hair reduction. of permanent Permanent iberate yourself from the constant need to shave hair reduction. L and wax unwanted facial and body hair in order to feel and look your best. With light-based perma- SCHEDULE YOUR TREATMENT Hair Reduction nent hair reduction, just a few simple treatments SESSION TODAY—AND BE FREE is all it takes to permanently minimize hair growth, OF UNWANTED HAIR. revealing clear, silky skin that’s ready to bare every day—and all year long. Unlike shaving that lasts days, waxing that needs to be repeated every few weeks indefinitely, or elec- trolysis that’s tedious, permanent hair reduction is a lasting solution that takes away the everyday hassle of dealing with unwanted facial and body hair. The secret lies in the light-based technology that targets and destroys hair cells responsible for hair growth without harming surrounding skin. It’s a simple approach to permanent hair reduction that’s fast, easy and FDA-cleared. Best of all, treatment sessions take just minutes and are practically pain-free. It’s the hair removal solution you’ve been waiting for. Make the Move to Permanent Hair Reduction. Ideal for: Faces • Underarms • Arms • Legs Back • Bikini area • Chest Your provider has chosen Palomar® products for your treatment. Palomar produces the most advanced cos- metic lasers and pulsed light systems to dramatically improve the appearance of skin. Permanent hair reduction is available www.palomarmedical.com for any skin type and most hair colors.
    [Show full text]
  • Re-Visiting Hypersensitivity Reactions to Taxanes: a Comprehensive Review
    Clinic Rev Allerg Immunol DOI 10.1007/s12016-014-8416-0 Re-visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review Matthieu Picard & Mariana C. Castells # Springer Science+Business Media New York 2014 Abstract Taxanes (a class of chemotherapeutic agents) Keywords Taxane . Paclitaxel . Taxol . Docetaxel . are an important cause of hypersensitivity reactions Taxotere . Nab-paclitaxel . Abraxane . Cabazitaxel . (HSRs) in cancer patients. During the last decade, the Chemotherapy . Hypersensitivity . Allergy . Skin test . development of rapid drug desensitization has been key Desensitization . Challenge . Diagnosis . Review . IgE . to allow patients with HSRs to taxanes to be safely re- Complement . Mechanism treated although the mechanisms of these HSRs are not fully understood. Earlier studies suggested that solvents, such as Cremophor EL used to solubilize paclitaxel, Introduction were responsible for HSRs through complement activa- tion, but recent findings have raised the possibility that Hypersensitivity reactions (HSRs) to chemotherapy are in- some of these HSRs are IgE-mediated. Taxane skin creasingly common and represent an important impediment testing, which identifies patients with an IgE-mediated to the care of cancer patients as they may entail serious sensitivity, appears as a promising diagnostic and risk consequences and prevent patients from being treated with stratification tool in the management of patients with the most efficacious agent against their cancer [1]. During the HSRs to taxanes. The management of patients following last decade, different groups have developed rapid drug de- a HSR involves risk stratification and re-exposure could sensitization (RDD) protocols that allow the safe re- be performed either through rapid drug desensitization introduction of a chemotherapeutic agent to which a patient or graded challenge based on the severity of the initial is allergic, and their use have recently been endorsed by the HSR and the skin test result.
    [Show full text]
  • Antiproliferative Effects of Free and Encapsulated Hypericum Perforatum L
    ISSN 2093-6966 [Print], ISSN 2234-6856 [Online] Journal of Pharmacopuncture 2019;22[2]:102-108 DOI: https://doi.org/10.3831/KPI.2019.22.013 Original article Antiproliferative Effects of Free and Encapsulated Hypericum Perforatum L. Extract and Its Potential Interaction with Doxorubicin for Esophageal Squamous Cell Carcinoma Issa Amjadi1, Mohammad Mohajeri2, Andrei Borisov3 , Motahare-Sadat Hosseini4* 1 Department of Biomedical Engineering, Wayne State University, Detroit, United States 2 Department of Medical Biotechnology, Mashhad University of Medical Sciences, Mashhad, Iran 3 Department of Biomedical Engineering, Wayne State University, Detroit, United States 4 Biomaterials Group, Department of Biomedical Engineering, Amirkabir University of Technology, Tehran, Iran Key Words Results: Free drugs and nanoparticles significantly inhibited KYSE30 cells by 55-73% and slightly affected doxorubicin, hypericum perforatum extract, nano- normal cells up to 29%. The IC50 of Dox NPs and HP particles, esophageal squamous cell carcinoma, drug NPs was ~ 0.04-0.06 mg/mL and ~ 0.6-0.7 mg/mL, re- resistance spectively. Significant decrease occurred in cyclin D1 expression by Dox NPs and HP NPs (P < 0.05). Expo- Abstract sure of KYSE-30 cells to combined treatments includ- ing both Dox and HP extract significantly increased the Objectives: Esophageal squamous cell carcinoma level of cyclin D1 expression as compared to those with (ESCC) is considered as a deadly medical condition that individual treatments (P < 0.05). affects a growing number of people worldwide. Target- ed therapy of ESCC has been suggested recently and Conclusion: Dox NPs and HP NPs can successfully and required extensive research. With cyclin D1 as a thera- specifically target ESCC cells through downregulation peutic target, the present study aimed at evaluating the of cyclin D1.
    [Show full text]
  • Chemotherapy Protocol
    Chemotherapy Protocol BREAST CANCER CYCLOPHOSPHAMIDE-EPIRUBICIN-PACLITAXEL (7 day) Regimen • Breast Cancer – Cyclophosphamide-Epirubicin-Paclitaxel (7 day) Indication • Neoadjuvant / adjuvant therapy of early breast cancer • WHO Performance status 0, 1 Toxicity Drug Adverse Effect Cyclophosphamide Dysuria, haemorrhagic cystitis, taste disturbances Epirubicin Cardio-toxicity, urinary discolouration (red) Hypersensitivity, hypotension, bradycardia, peripheral Paclitaxel neuropathy, myalgia and back pain on administration The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details. Monitoring Regimen • FBC, U&Es and LFTs prior to each cycle. • Ensure adequate cardiac function before starting treatment with epirubicin. Baseline LVEF should be measured, particularly in patients with a history of cardiac problems or in the elderly. Dose Modifications The dose modifications listed are for haematological, liver and renal function only. Dose adjustments may be necessary for other toxicities as well. In principle all dose reductions due to adverse drug reactions should not be re- escalated in subsequent cycles without consultant approval. It is also a general rule for chemotherapy that if a third dose reduction is necessary treatment should be stopped. Please discuss all dose reductions / delays with the relevant consultant before prescribing if appropriate. The approach may be different depending on the clinical circumstances. The following is a general guide only. Version 1.2 (November 2020) Page 1 of 7 Breast – Cyclophosphamide-Epirubicin-Paclitaxel (7 day) Haematological Prior to prescribing the following treatment criteria must be met on day one of treatment. Criteria Eligible Level Neutrophils equal to or more than 1x10 9/L Platelets equal to or more than 100x10 9/L Consider blood transfusion if patient symptomatic of anaemia or has a haemoglobin of less than 8g/dL If counts on day one are below these criteria for neutrophils and platelets then delay treatment for seven days.
    [Show full text]
  • An Amerind Etymological Dictionary
    An Amerind Etymological Dictionary c 2007 by Merritt Ruhlen ! Printed in the United States of America Library of Congress Cataloging-in-Publication Data Greenberg, Joseph H. Ruhlen, Merritt An Amerind Etymological Dictionary Bibliography: p. Includes indexes. 1. Amerind Languages—Etymology—Classification. I. Title. P000.G0 2007 000!.012 00-00000 ISBN 0-0000-0000-0 (alk. paper) This book is dedicated to the Amerind people, the first Americans Preface The present volume is a revison, extension, and refinement of the ev- idence for the Amerind linguistic family that was initially offered in Greenberg (1987). This revision entails (1) the correction of a num- ber of forms, and the elimination of others, on the basis of criticism by specialists in various Amerind languages; (2) the consolidation of certain Amerind subgroup etymologies (given in Greenberg 1987) into Amerind etymologies; (3) the addition of many reconstructions from different levels of Amerind, based on a comprehensive database of all known reconstructions for Amerind subfamilies; and, finally, (4) the addition of a number of new Amerind etymologies presented here for the first time. I believe the present work represents an advance over the original, but it is at the same time simply one step forward on a project that will never be finished. M. R. September 2007 Contents Introduction 1 Dictionary 11 Maps 272 Classification of Amerind Languages 274 References 283 Semantic Index 296 Introduction This volume presents the lexical and grammatical evidence that defines the Amerind linguistic family. The evidence is presented in terms of 913 etymolo- gies, arranged alphabetically according to the English gloss.
    [Show full text]
  • The Hairlessness Norm Extended: Reasons for and Predictors of Women’S Body Hair Removal at Different Body Sites
    Sex Roles (2008) 59:889–897 DOI 10.1007/s11199-008-9494-3 ORIGINAL ARTICLE The Hairlessness Norm Extended: Reasons for and Predictors of Women’s Body Hair Removal at Different Body Sites Marika Tiggemann & Suzanna Hodgson Published online: 18 June 2008 # Springer Science + Business Media, LLC 2008 Abstract The study aimed to explore the motivations prescription renders many women not only perpetually behind and predictors of the practice of body hair removal dissatisfied with their bodies (Rodin et al. 1985), but also among women. A sample of 235 Australian female highly motivated to alter their bodies to match the ideal, as undergraduate students completed questionnaires asking illustrated by the existence of multi-million dollar diet, about the frequency and reasons for body hair removal, as exercise, cosmetic and cosmetic surgery industries. well as measures of media exposure. It was confirmed that One particular aspect of the ideal that has received the vast majority (approximately 96%) regularly remove relatively little research attention or theorizing is the their leg and underarm hair, most frequently by shaving, prescription for smooth hairless skin. This is most likely and attribute this to femininity and attractiveness reasons. A because the practice of removing unwanted body hair is so sizeable proportion (60%) also removed at least some of normative in Western cultures as to go unremarked. By far their pubic hair, with 48% removing most or all of it. Here the majority of women in the USA (Basow 1991), UK the attributions were relatively more to sexual attractiveness (Toerien et al. 2005) and Australia (Tiggemann and Kenyon and self-enhancement.
    [Show full text]
  • Inhibition of Tumour Cell Growth by Hyperforin, a Novel Anticancer Drug from St
    Oncogene (2002) 21, 1242 ± 1250 ã 2002 Nature Publishing Group All rights reserved 0950 ± 9232/02 $25.00 www.nature.com/onc Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis Christoph M Schempp*,1, Vladimir Kirkin2, Birgit Simon-Haarhaus1, Astrid Kersten3, Judit Kiss1, Christian C Termeer1, Bernhard Gilb4, Thomas Kaufmann5, Christoph Borner5, Jonathan P Sleeman2 and Jan C Simon1 1Department of Dermatology, University of Freiburg, Hauptstrasse 7, D-79104 Freiburg, Germany; 2Institute of Genetics, Forschungszentrum Karlsruhe, PO Box 3640, D-76021 Karlsruhe, Germany; 3Institute of Pathology, University of Freiburg, Albertstrasse 19, D-79104 Freiburg, Germany; 4HWI Analytik, Hauptstrasse 28, 78106 Rheinzabern, Germany; 5Institute of Molecular Medicine, University of Freiburg, Breisacherstr. 66, D-79106 Freiburg, Germany Hyperforin is a plant derived antibiotic from St. John's Introduction wort. Here we describe a novel activity of hyperforin, namely its ability to inhibit the growth of tumour cells by An exciting aspect of apoptosis is that it can be utilized induction of apoptosis. Hyperforin inhibited the growth of in the treatment of cancer (Revillard et al., 1998; various human and rat tumour cell lines in vivo, with IC50 Nicholson, 2000). Anticancer agents with dierent values between 3 ± 15 mM. Treatment of tumour cells with modes of action have been reported to trigger hyperforin resulted in a dose-dependent generation of apoptosis in chemosensitive cells (Hickman, 1992; apoptotic oligonucleosomes, typical DNA-laddering and Debatin, 1999). The process of apoptosis consists of apoptosis-speci®c morphological changes. In MT-450 dierent phases, including initiation, execution and mammary carcinoma cells hyperforin increased the activity degradation (Kroemer, 1997), and is activated by two of caspase-9 and caspase-3, and hyperforin-mediated major pathways.
    [Show full text]
  • A-Kinase Anchoring Protein 79/150 Scaffolds Transient Receptor Potential a 1 Phosphorylation and Sensitization by Metabotropic G
    www.nature.com/scientificreports OPEN A-Kinase Anchoring Protein 79/150 Scaffolds Transient Receptor Potential A 1 Phosphorylation and Received: 25 November 2016 Accepted: 5 April 2017 Sensitization by Metabotropic Published: xx xx xxxx Glutamate Receptor Activation Allison Doyle Brackley1, Ruben Gomez2, Kristi A. Guerrero2, Armen N. Akopian3, Marc J. Glucksman5, Junhui Du5, Susan M. Carlton6 & Nathaniel A. Jeske1,2,4 Mechanical pain serves as a base clinical symptom for many of the world’s most debilitating syndromes. Ion channels expressed by peripheral sensory neurons largely contribute to mechanical hypersensitivity. Transient Receptor Potential A 1 (TRPA1) is a ligand-gated ion channel that contributes to inflammatory mechanical hypersensitivity, yet little is known as to the post-translational mechanism behind its somatosensitization. Here, we utilize biochemical, electrophysiological, and behavioral measures to demonstrate that metabotropic glutamate receptor-induced sensitization of TRPA1 nociceptors stimulates targeted modification of the receptor. Type 1 mGluR5 activation increases TRPA1 receptor agonist sensitivity in an AKA-dependent manner. As a scaffolding protein for Protein Kinases A and C (PKA and PKC, respectively), AKAP facilitates phosphorylation and sensitization of TRPA1 in ex vivo sensory neuronal preparations. Furthermore, hyperalgesic priming of mechanical hypersensitivity requires both TRPA1 and AKAP. Collectively, these results identify a novel AKAP-mediated biochemical mechanism that increases TRPA1 sensitivity in peripheral sensory neurons, and likely contributes to persistent mechanical hypersensitivity. A-kinase Anchoring Protein 79/150 (AKAP) is a scaffolding protein expressed throughout neural tissues1. Importantly, AKAP facilitates post-translational modifications of plasma membrane receptors by kinases includ- ing Protein Kinase A (PKA) and Protein Kinase C (PKC2).
    [Show full text]
  • Menopause and Hair Loss
    Menopause and Hair loss Written by Consultant Dermatologist, Dr Sajjad Rajpar Many women will experience concerns with their hair during or after the menopause. This can come as quite a shock and can be deeply worrying because hair is such an important aspect of self­identity. Hair loss may not be obvious to anyone else at first, and convincing others (including relatives and family doctors) that there is a problem can be a hurdle in itself. The signs may be an increasing loss of hair when brushing or in the shower, general thinning, the hair line moving backwards, and dry or brittle hair. The parting may widen, and more scalp may show through the hair, especially when the hair is wet. There can be anxiety with brushing or washing the hair, or even looking in the mirror. Stress from hair loss is worsened by not knowing whether the condition will deteriorate and whether HRT will help or not. It can be confusing trying to make sense of the sea of supplements and tonics on the internet or recommended by trichologists and hairdressers. Who gets hair loss? Some 40% of women will experience hair loss after the menopause. In two thirds of women this will be all over the scalp. For the remainder, the hair loss is over the front or temples only. Hair loss may start during the perimenopause or occur many years after. Why does hair loss occur with the menopause? While a hair follicle is only tiny, it is an extremely complex structure that is still not well understood, especially when it comes to hormonal changes.
    [Show full text]
  • Variation of Human Hairiness: a Possible Adaptation to Solar Radiation and Melanin
    Amrita Dhugga, Maciej Henneberg, Jaliya Kumaratilake Skin colour and hairiness ANTHROPOLOGICAL REVIEW • Vol. 77 (2), 219–232 (2014) ANTHROPOLOGICAL REVIEW Available online at: www.degruyter.com Journal homepage: www.ptantropologiczne.pl Variation of human hairiness: a possible adaptation to solar radiation and melanin Amrita Dhugga, Maciej Henneberg, Jaliya Kumaratilake Biological Anthropology and Comparative Anatomy Unit, The University of Adelaide ABSTRACT: Many theories have been advanced to explain human hairlessness, however, there is no consen- sus. This study of 76 males observed that skin reflectance measuring skin colouration and melanin pig- mentation correlated with hair size and follicle density. Individuals with a greater concentration of melanin within the superficial layer of the skin had a lower follicle density and smaller sizes of hairs. In contrast, individuals with a lower melanin concentration and lighter skin colour had a full range of hairiness. This leads to the suggestion that over the course of human evolution, high concentrations of melanin in consist- ently exposed to ultraviolet radiation areas developed first and that hair loss was a consequence of compe- tition in the skin between melanin production and hair growth. Darker pigmented skin and lower follicle density are significantly correlated (R2=0.283; p<0.05). Individuals with darker skin had a mean of 4.91 follicles per cm2 whereas those with lighter skin reflectance had 11.20 follicles per cm2. This suggests that increased concentrations of melanin in the basal layer of the epidermis may limit hairiness by negatively influencing the skin’s ability to produce hair. KEY WORDS: evolution of hair, Von Luschan’s Scale, skin colour reflectance, hairiness Introduction become shorter and thinner (Morgan 1982).
    [Show full text]
  • HP6389/00 Philips Touch up Precision Trimmer
    touch up precision trimmer Face, eyebrows, fine body hairs HP6389/00 Stay flawless on the go No eyebrow, face or body hair out of place Maintain brows and smooth skin on-the-go. Satin Compact is a discrete beauty tool that makes it easy to precisely remove face and fine body hairs, when you realize you missed a spot. Quick and easy hair removal 1" trimming head for easy removal of fine body hairs 1/3" trimming head for easy removal of facial hairs Eyebrow shaping 2&4 mm eyebrow comb to uniform hair length Use on the go Small enough to take everywhere Convenient Cleaning brush included so you can keep the trimmer hygienic touch up precision trimmer HP6389/00 Highlights Specifications Touch-up body attachment Eyebrow shaper Features Body version trimming unit: 1 in trimmer head for facial hairs: 1/3 in Accessories Cleaning brush Protection cap: No Eyebrow comb: No Technical specifications The body application trimming head is ideal for With 2 length options, 2mm and 4mm, to trim Color(s): Glossy white quick touch-ups on-the-go. The 26mm trimming hair to the precise length you want. Simply Power source: 1 x AAA-type alkaline battery head ensures quick and easy use on small body attach the comb onto the trimming head to (included) areas (e.g. toes, knee). achieve a precise and uniformed result. Voltage: 1.5V DC Precise face attachment Compact and portable Dimensions F-box Dimensions: 80 x 40 x 175mm Service 2-year guarantee The face application trimming head is great for Small enough to fit in a handbag or clutch and quick touch-ups on-the-go.
    [Show full text]